Attached files
| file | filename |
|---|---|
| 10-K - 10-K - AGIOS PHARMACEUTICALS, INC. | agio-123117x10k.htm |
| EX-32.2 - EXHIBIT 32.2 - AGIOS PHARMACEUTICALS, INC. | agio-ex322x123117.htm |
| EX-32.1 - EXHIBIT 32.1 - AGIOS PHARMACEUTICALS, INC. | agio-ex321x123117.htm |
| EX-31.2 - EXHIBIT 31.2 - AGIOS PHARMACEUTICALS, INC. | agio-ex312x123117.htm |
| EX-31.1 - EXHIBIT 31.1 - AGIOS PHARMACEUTICALS, INC. | agio-ex311x123117.htm |
| EX-23.2 - EXHIBIT 23.2 - AGIOS PHARMACEUTICALS, INC. | agio-ex232x123117.htm |
| EX-21.1 - EXHIBIT 21.1 - AGIOS PHARMACEUTICALS, INC. | agio-ex211x123117.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S‑8 (Nos. 333-216106, 333-209755, 333-201796, 333-193802, and 333-190101) and S-3 (No. 333-221960) of Agios Pharmaceuticals, Inc. of our report dated February 14, 2018 relating to the financial statements and the effectiveness of internal controls over financial reporting, which appears in this Form 10‑K.
/s/ Pricewaterhouse Coopers LLP
Boston, Massachusetts
February 14, 2018